CytoSorbents Corp (CytoSorbents) is a medical device company that focuses on treating life-threatening conditions in the ICU and cardiac surgery using blood purification. It offers products such as CytoSorb, HemoDefend, ECOS-300CY, DrugSorb-ATR and VetResQ. The company's flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriously ill patients by reducing excessive cytokines and bacterial toxins. CytoSorbents offers DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood, VetResQ, a blood purification adsorber, to support and treat excessive inflammation and toxic injury in animals. The company offers its products through a network of distributors across Europe, the Middle East and Asia Pacific. CytoSorbents is headquartered in Monmouth Junction, New Jersey, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company CytoSorbents Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- CytoSorbents Corp Company Overview
- CytoSorbents Corp Company Snapshot
- CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview
- CytoSorbents Corp - Pipeline Analysis Overview
- CytoSorbents Corp - Key Facts
- CytoSorbents Corp - Major Products and Services
- CytoSorbents Corp Pipeline Products by Development Stage
- CytoSorbents Corp Ongoing Clinical Trials by Trial Status
- CytoSorbents Corp Pipeline Products Overview
- BetaSorb
- BetaSorb Product Overview
- ContrastSorb
- ContrastSorb Product Overview
- CST 301
- CST 301 Product Overview
- CytoSorb
- CytoSorb Product Overview
- CytoSorb Clinical Trial
- CytoSorb-XL
- CytoSorb-XL Product Overview
- DrugSorb-ATR
- DrugSorb-ATR Product Overview
- HemoDefend BGA
- HemoDefend BGA Product Overview
- HemoDefend RBC
- HemoDefend RBC Product Overview
- K+ontrol
- K+ontrol Product Overview
- CytoSorbents Corp - Key Competitors
- CytoSorbents Corp - Key Employees
- CytoSorbents Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- CytoSorbents Corp, Recent Developments
- Jan 17, 2024: Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients
- Dec 28, 2023: Cytosorbents Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
- Sep 19, 2023: CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
- Sep 01, 2023: CytoSorbents receives expanded registration from ANVISA for CytoSorb
- Aug 14, 2023: CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial
- Jul 07, 2023: CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
- Apr 20, 2023: CytoSorbents’ pivotal STAR-T trial reaches second key milestone with 80 patients enrolled
- Mar 29, 2023: Landmark publication underscores robust ability of CytoSorb to reduce cytokine storm during systemic hyperinflammation
- Mar 09, 2023: CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
- Mar 07, 2023: New European “Guidelines for the Management of Severe Perioperative Bleeding” consider hemoadsorption for the first-time
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview
- CytoSorbents Corp Pipeline Products by Equipment Type
- CytoSorbents Corp Pipeline Products by Indication
- CytoSorbents Corp Ongoing Clinical Trials by Trial Status
- CytoSorbents Corp, Key Facts
- CytoSorbents Corp, Major Products and Services
- CytoSorbents Corp Number of Pipeline Products by Development Stage
- CytoSorbents Corp Pipeline Products Summary by Development Stage
- CytoSorbents Corp Ongoing Clinical Trials by Trial Status
- CytoSorbents Corp Ongoing Clinical Trials Summary
- BetaSorb - Product Status
- BetaSorb - Product Description
- ContrastSorb - Product Status
- ContrastSorb - Product Description
- CST 301 - Product Status
- CST 301 - Product Description
- CytoSorb - Product Status
- CytoSorb - Product Description
- CytoSorb - A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb 300 ml Device for Shock Reversal in Patients with Vasoplegic Septic Shock
- CytoSorb - COOLEY - Study: Acute on Chronic Liver Failure Using the Cytosorb Device
- CytoSorb - Cytokine Adsorption in Patients with Acute-on-chronic Liver Failure (CYTOHEP) - A Single Center, Open-label, Randomized, Controlled Intervention Trial
- CytoSorb - Cytokine Filter Usage During Open Thoracoabdominal Aortic Aneurysm Repair - A Single-center Randomized Prospective Trial - Cytosorb and Its Impact on Open TAAA Repair Outcome
- CytoSorb - Cytokine Filtration in Lung Transplantation - a Randomised, Controlled, Multicentre Clinical Trial (GLUSorb)
- CytoSorb - Cytosorb Modulation of Surgical Inflammation During LVAD Insertion
- CytoSorb - CytoSorb Treatment of Critically Ill Patients Registry: International Registry on the Use of CytoSorb in the Critical Care Setting
- CytoSorb - Development and Use of a Population Pharmacokinetic Model of Amikacin and Vancomycin for the Optimization of Dosing Regimens in Critically Ill Patients on Different Modalities of Extracorporeal Hemoadsorption
- CytoSorb - ECMOsorb Trial - Impact of a VA-ECMO in Combination with CytoSorb in Critically Ill Patients with Cardiogenic Shock - A Prospective, Randomized, Blinded, Monocenter Trial
- CytoSorb - Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation
- CytoSorb - Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)
- CytoSorb - Prevention of Vasoplegia with the Use of CytoSorb
- CytoSorb - Removal of Cytokines With Cytosorbents After Inflammatory Response Reaction During Cardiac Surgery and Association of Endothelial Progenitor Cells
- CytoSorb - Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting
- CytoSorb - The Effect of the CytoSorb Filter to Remove Anticoagulants From the Circulation During Emergency Surgery for Aortic Dissection
- CytoSorb-XL - Product Status
- CytoSorb-XL - Product Description
- DrugSorb-ATR - Product Status
- DrugSorb-ATR - Product Description
- HemoDefend BGA - Product Status
- HemoDefend BGA - Product Description
- HemoDefend RBC - Product Status
- HemoDefend RBC - Product Description
- K+ontrol - Product Status
- K+ontrol - Product Description
- CytoSorbents Corp, Key Employees
- CytoSorbents Corp, Subsidiaries
- Glossary
- CytoSorbents Corp Pipeline Products by Equipment Type
- CytoSorbents Corp Pipeline Products by Development Stage
- CytoSorbents Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aethlon Medical Inc
- NxStage Medical Inc
- Hologic Inc
- HemoCleanse Technologies LLC
- Biomatrica Inc
